JP3893286B2 - α−インターフェロンの水溶液製剤 - Google Patents

α−インターフェロンの水溶液製剤 Download PDF

Info

Publication number
JP3893286B2
JP3893286B2 JP2001537977A JP2001537977A JP3893286B2 JP 3893286 B2 JP3893286 B2 JP 3893286B2 JP 2001537977 A JP2001537977 A JP 2001537977A JP 2001537977 A JP2001537977 A JP 2001537977A JP 3893286 B2 JP3893286 B2 JP 3893286B2
Authority
JP
Japan
Prior art keywords
interferon
aqueous solution
formulation
aqueous
phenol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001537977A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003514027A (ja
Inventor
ケオル カン，ヨン
リー，サン−ヘオン
ハン，キュボエム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG Corp
Original Assignee
LG Chem Investment Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LG Chem Investment Co Ltd filed Critical LG Chem Investment Co Ltd
Publication of JP2003514027A publication Critical patent/JP2003514027A/ja
Application granted granted Critical
Publication of JP3893286B2 publication Critical patent/JP3893286B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
JP2001537977A 1999-11-19 2000-11-17 α−インターフェロンの水溶液製剤 Expired - Fee Related JP3893286B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-1999-0051481A KR100399156B1 (ko) 1999-11-19 1999-11-19 α-인터페론의 용액제형
KR1999/51481 1999-11-19
PCT/KR2000/001322 WO2001035987A1 (en) 1999-11-19 2000-11-17 An aqueous solution formulation of alpha-interferon

Publications (2)

Publication Number Publication Date
JP2003514027A JP2003514027A (ja) 2003-04-15
JP3893286B2 true JP3893286B2 (ja) 2007-03-14

Family

ID=36782398

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001537977A Expired - Fee Related JP3893286B2 (ja) 1999-11-19 2000-11-17 α−インターフェロンの水溶液製剤

Country Status (23)

Country Link
EP (1) EP1231933B1 (de)
JP (1) JP3893286B2 (de)
KR (1) KR100399156B1 (de)
CN (1) CN1203892C (de)
AR (1) AR026507A1 (de)
AT (1) ATE333891T1 (de)
AU (1) AU777994B2 (de)
BR (1) BR0015699A (de)
CA (1) CA2391889A1 (de)
CY (1) CY1105449T1 (de)
DE (1) DE60029614T2 (de)
DK (1) DK1231933T3 (de)
ES (1) ES2267584T3 (de)
HU (1) HUP0203706A3 (de)
MX (1) MXPA02005105A (de)
PE (1) PE20010903A1 (de)
PL (1) PL356406A1 (de)
PT (1) PT1231933E (de)
RU (1) RU2232595C2 (de)
TR (1) TR200201310T2 (de)
TW (1) TWI223596B (de)
WO (1) WO2001035987A1 (de)
ZA (1) ZA200204096B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8551469B2 (en) 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US6830744B2 (en) * 2002-05-31 2004-12-14 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
RU2447897C2 (ru) * 2009-03-26 2012-04-20 Сергей Юрьевич Родионов Цитокинсодержащая композиция для лечения вирусных заболеваний
CN107496917B (zh) 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
WO2011147921A1 (en) 2010-05-28 2011-12-01 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
SG11201502930XA (en) 2012-10-26 2015-05-28 Lupin Ltd Stable pharmaceutical composition of peginterferon alpha-2b
CN104888196B (zh) * 2015-06-25 2018-07-06 北京三元基因药业股份有限公司 一种稳定的干扰素α多剂量笔注射液
CN105456186A (zh) * 2015-12-24 2016-04-06 杭州嘉伟生物制品有限公司 一种生理平衡液的制备方法
CN114053397B (zh) * 2022-01-17 2022-12-20 北京三元基因药业股份有限公司 一种稳定的干扰素多剂量注射液及其制备方法
CN115068592A (zh) * 2022-06-27 2022-09-20 长春生物制品研究所有限责任公司 开封后常温稳定的重组人干扰素α1b滴眼液及制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution

Also Published As

Publication number Publication date
KR20010047312A (ko) 2001-06-15
EP1231933A1 (de) 2002-08-21
ATE333891T1 (de) 2006-08-15
ZA200204096B (en) 2003-02-26
HUP0203706A2 (hu) 2003-03-28
AU777994B2 (en) 2004-11-11
CN1203892C (zh) 2005-06-01
JP2003514027A (ja) 2003-04-15
MXPA02005105A (es) 2002-11-07
PT1231933E (pt) 2006-10-31
DK1231933T3 (da) 2006-10-30
ES2267584T3 (es) 2007-03-16
PL356406A1 (en) 2004-06-28
DE60029614D1 (de) 2006-09-07
KR100399156B1 (ko) 2003-09-26
AR026507A1 (es) 2003-02-12
PE20010903A1 (es) 2001-08-31
CA2391889A1 (en) 2001-05-25
EP1231933B1 (de) 2006-07-26
RU2232595C2 (ru) 2004-07-20
AU1421601A (en) 2001-05-30
WO2001035987A1 (en) 2001-05-25
BR0015699A (pt) 2002-07-23
TWI223596B (en) 2004-11-11
CY1105449T1 (el) 2010-04-28
TR200201310T2 (tr) 2002-09-23
RU2002116364A (ru) 2004-01-20
HUP0203706A3 (en) 2004-12-28
CN1391478A (zh) 2003-01-15
DE60029614T2 (de) 2007-07-12

Similar Documents

Publication Publication Date Title
US4847079A (en) Biologically stable interferon compositions comprising thimerosal
JP3893286B2 (ja) α−インターフェロンの水溶液製剤
US4680175A (en) Interferon administration vehicles
JP3978228B2 (ja) 安定な、水性αインターフェロン溶液処方物
US5981485A (en) Human growth hormone aqueous formulation
CA2139358C (en) Human growth hormone aqueous formulation
US5763394A (en) Human growth hormone aqueous formulation
CA2275890A1 (en) Stable liquid interferon formulations
HU227421B1 (en) Process for producing liquid, preserved, buffered medicament containing human proteins for the purposes of infusion or injection
Sutton et al. Some observations on interferon prepared in tissue cultures
HU225147B1 (en) Stabile liquide composition containing urate oxydase, and lyophilised product for its preparation
US20030170207A1 (en) Stable aqua formulation of interferon, the preparation method and the uses thereof
US5714458A (en) Stable pharmaceutical compositions containing a fibroblast growth factor
EP0539408B1 (de) Stabilisierte zusammensetzung enthaltend ein fibroblastwachstumsfaktor
CN114470167A (zh) 一种干扰素滴眼液及其制备方法
CA1295240C (en) Biologically stable interferon compositions
KR19990085129A (ko) 안정한 α-인터페론 용액 제제
KR100331381B1 (ko) 우레이트옥시디아제를함유하는안정한액체조성물및그의제조를위한동결건조조성물
JPH10259138A (ja) ペプチドの安定化方法および当該方法を用いたペプチド含有凍結乾燥医薬組成物

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060530

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060830

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20061010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061017

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20061114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20061211

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees